Collegium Pharmaceutical, Inc. Forecast, price target & analysts
Collegium Pharmaceutical, Inc. Target price 2026 - Analyst rating & recommendation
Collegium Pharmaceutical, Inc. Classifications & Recommendation
Collegium Pharmaceutical, Inc. Price Target
| Target Price | $48.96 |
| Price | $22.09 |
| Potential |
121.64%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2027 .
The average Collegium Pharmaceutical, Inc. target price is $48.96.
This is
121.64%
register free of charge
$63.00
185.20%
register free of charge
$43.43
96.60%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2027 of
121.64%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 780.57 | 852.96 |
| 23.62% | 9.27% | |
| EBITDA Margin | 51.98% | 54.51% |
| 3.20% | 4.88% | |
| Net Margin | 8.05% | 28.61% |
| 26.49% | 255.21% |
9 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2026 . The average Collegium Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2026. The average Collegium Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2026. The average Collegium Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.58 | 7.51 |
| 7.60% | 375.32% | |
| P/E | 2.94 | |
| EV/Sales | 2.11 |
9 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Collegium Pharmaceutical, Inc....
Current Collegium Pharmaceutical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 19 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 20 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 19 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 20 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
